Patents Issued in November 6, 2018
  • Patent number: 10118935
    Abstract: The present disclosure provides dimers of melampomagnolide B (MMB), including carbamate, carbonate, succinic amide, ester and carboxamide dimers of MMB. These derivatives are useful for treating cancer in humans, in particular in treating leukemia, including acute myelogenous leukemia (AML).
    Type: Grant
    Filed: April 19, 2018
    Date of Patent: November 6, 2018
    Assignees: BioVentures, LLC, The Regents of the University of Colorado
    Inventors: Venumadhav Janganati, Peter Crooks, Narsimha Reddy Penthala, Craig Jordan, Shobanbabu Bommagani, Jessica Ponder
  • Patent number: 10118936
    Abstract: The present invention is directed to arginase inhibitor compounds of formula IA or formula IB: or a pharmaceutically acceptable salt thereof, compositions containing these compounds, and methods of their use for the treatment and diagnosis of conditions characterized by upregulation of arginase, abnormally high arginase activity, or by abnormally low nitric oxide synthase activity.
    Type: Grant
    Filed: December 4, 2015
    Date of Patent: November 6, 2018
    Assignees: The Trustees of the University of Pennsylvania, AstraZeneca AB
    Inventors: David W. Christianson, Bruce Edward Tomczuk, Richard Scott Pottorf, Andrew Vargha Colasanti, Gary Lee Olson
  • Patent number: 10118937
    Abstract: A process for making ixazomib citrate of formula VI comprising reacting a compound of formula V with citric acid to form ixazomib citrate of formula VI: wherein R is hydrogen or an amide protecting group.
    Type: Grant
    Filed: January 3, 2018
    Date of Patent: November 6, 2018
    Assignee: SCINOPHARM TAIWAN, LTD.
    Inventors: Tsung-Yu Hsiao, Jyh-Hsiung Liao
  • Patent number: 10118938
    Abstract: Disclosed herein are methods of treating a cancer cell that include contacting a cancer cell with a compound having the structure of formula (I) M is Pt, Pd or Ni; Q is As, Sb or Bi; Z1 is N; Z2 is O or S; L1 and L2 are independently C(O), C—R1 or C—R2; X is a Lewis base; Y1 and Y2 are independently selected from —OR3, —OR4, —SR3 and —SR4, wherein R1 and R2 are independently selected from hydrogen, halogen, cyano, keto, ester, ether, thiol, thioether, thioester, imino, C1-C10 alkyl, C1-C10 alkenyl, alkynyl, alkoxyl, amino, amidyl, immino, sulfonyl, sulfoxyl, phosphoryl, phosphoryl ester, glycosyl, aryl, C3-C15 cycloalkyl, heteroaryl, and C3-C15 heterocycloalkyl; and R3 and R4 are independently selected from hydrogen, C1-C10 alkyl, C1-C10 alkenyl, alkynyl, alkoxyl, amino, amidyl, immino, sulfonyl, sulfoxyl, phosphoryl, phosphoryl ester, glycosyl, aryl, C3-C15 cycloalkyl, heteroaryl, and C3-C15 heterocycloalkyl.
    Type: Grant
    Filed: June 29, 2017
    Date of Patent: November 6, 2018
    Assignee: NORTHWESTERN UNIVERSITY
    Inventors: Denana U. Miodragovic, Thomas V. O'Halloran
  • Patent number: 10118939
    Abstract: Cyclometallated Ir complex comprising three N,N diaryl substituted carbene ligands, bearing substituents in the 2 position of the non-cyclometallated aryl ring; an organic electronic device, preferably an organic light-emitting diode (OLED), comprising at least one cyclometallated Ir complex as described above, a light-emitting layer comprising said cyclometallated Ir complex preferably as emitter material, preferably in combination with at least one host material, use of said cyclometallated Ir complex in an OLED and an apparatus selected from the group consisting of stationary visual display units, mobile visual display units, illumination units, units in items of clothing, units in handbags, units in accessories, units in furniture and units in wallpaper comprising said organic electronic device, preferably said OLED, or said light-emitting layer. The present invention further relates to a process for the preparation of said cyclometallated Ir complex.
    Type: Grant
    Filed: January 5, 2018
    Date of Patent: November 6, 2018
    Assignee: UDC IRELAND LIMITED
    Inventors: Stefan Metz, Korinna Dormann, Glauco Battagliarin, Christian Eickhoff, Flavio Luiz Benedito, Soichi Watanabe, Gerhard Wagenblast, Thomas Geßner, Christian Lennartz, Peter Murer
  • Patent number: 10118940
    Abstract: An alkoxide compound represented by the following formula (I), and a raw material for thin film formation containing the alkoxide compound. In the formula, R1 represents a linear or branched alkyl group having 2 to 4 carbon atoms, and R2 and R3 each represent a linear or branched alkyl group having 1 to 4 carbon atoms. In the formula (I), R1 is preferably an ethyl group. It is also preferred that one or both of R2 and R3 be an ethyl group. The raw material for thin film formation including an alkoxide compound represented by general formula (I) is preferably used as a raw material for chemical vapor deposition.
    Type: Grant
    Filed: May 15, 2012
    Date of Patent: November 6, 2018
    Assignee: ADEKA CORPORATION
    Inventors: Senji Wada, Akio Saito, Tomoharu Yoshino
  • Patent number: 10118941
    Abstract: Methods for the preparation of diastereomerically pure phosphoramidate prodrugs of nucleosides, and intermediates useful for the preparation are provided. The nucleosides are useful for the treatment of hepatitis C and cancer.
    Type: Grant
    Filed: September 11, 2015
    Date of Patent: November 6, 2018
    Assignee: MEDIVIR AB
    Inventors: Pedro Pinho, Staffan Torssell
  • Patent number: 10118942
    Abstract: Disclosed are monoacylated Toll-like receptor 2 ligands which can be used in both the development of targeted agents for the imaging and treatment of pancreatic cancer as well as other cancers, and as an adjuvant for cancer immunotherapy. The monoacylated compounds disclosed herein have a higher binding affinity for TLR2 relative to a known potent diacylated agonists, but only ?½ the bioactivity. Competition of the monoacylated compound with the diacylated compound for binding TLR2 was confirmed. Hence, the reported monoacylated compounds are inhibitors/antagonists of TLR2 activation.
    Type: Grant
    Filed: March 25, 2016
    Date of Patent: November 6, 2018
    Assignees: H. Lee Moffitt Cancer Center and Research Institute, Inc., The Arizona Board of Regents on behalf of the University of Arizona, University of South Florida
    Inventors: David L. Morse, Josef Vagner, Mark McLaughlin, Robert Gillies, Amanda Huynh, Michael Doligalski
  • Patent number: 10118943
    Abstract: This invention provides novel compounds and methods for promoting cell survival and/or plasticity, especially in neuronal cells, by targeting the microtubule End Binding (EB) proteins and other associated proteins (e.g., drebrin). Methods for identifying potential modulators of cell death/plasticity are also described.
    Type: Grant
    Filed: March 12, 2013
    Date of Patent: November 6, 2018
    Assignee: Ramot at Tel-Aviv University Ltd.
    Inventors: Illana Gozes, Saar Oz, Jacqueline Woang Cheing Tiong
  • Patent number: 10118944
    Abstract: A cell-penetrating peptide characterized in that it comprises an amino acid sequence consisting of a beta-alanine or a serine in N-terminal position, linked to a sequence consisting of 9 consecutive amino acids from the sequence RXWXRLWXRLR (SEQ ID NO:7), wherein X in position 2 is R or S and X in positions 4 and 8 are, independently from each other, W or F.
    Type: Grant
    Filed: October 4, 2013
    Date of Patent: November 6, 2018
    Assignee: Aadigen LLC
    Inventors: Gilles Divita, Sebastien Deshayes, Karidia Konate, May Catherine Morris
  • Patent number: 10118945
    Abstract: Modified fungal strains having deleted gene clusters are provided. The modified fungal strains include A. nidulans. The deleted gene clusters are selected from the group of gene clusters responsible for the biosynthesis of sterigmatocystin, emericellamides, asperfuranone, monodictyphenone, terrequinone, F9775A, F9775B, asperthecin, and both portions of the split cluster that makes austinol and dehydroaustinol. Methods for making compounds by culturing the fungus in a growth media and separating the compound from the fungus and/or separating the compound from the growth media are included, as are the compounds and compositions comprising them.
    Type: Grant
    Filed: October 31, 2016
    Date of Patent: November 6, 2018
    Assignees: University of Kansas, University of Southern California
    Inventors: Berl Oakley, Manmeet Ahuja, Ruth Entwistle, Christine Oakley, Yi-Ming Chiang, Clay Wang
  • Patent number: 10118946
    Abstract: This invention provides novel guanylate cyclase C (GC-C) agonists and their therapeutic use. The agonists may be used either alone or in combination with one or more additional agents.
    Type: Grant
    Filed: June 14, 2017
    Date of Patent: November 6, 2018
    Assignee: SYNERGY PHARMACEUTICALS INC.
    Inventor: Kunwar Shailubhai
  • Patent number: 10118947
    Abstract: The invention describes peptide ligands specific for human plasma Kallikrein.
    Type: Grant
    Filed: April 11, 2014
    Date of Patent: November 6, 2018
    Assignee: BicycleRD Limited
    Inventors: Daniel Paul Teufel, Catherine Stace, Edward Walker, John Tite
  • Patent number: 10118948
    Abstract: Disclosed herein are novel antimicrobial peptides, pharmaceutical compositions containing the peptides, and methods of use of the peptides to inhibit the growth or proliferation of microbes. The antimicrobial peptides are particularly useful to treat infections of dangerous gram positive organisms such as MRSA and VRSA.
    Type: Grant
    Filed: December 7, 2016
    Date of Patent: November 6, 2018
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Jie Zheng, Ann Marie Knolhoff, Eric Wayne Brown, Timothy Ray Croley
  • Patent number: 10118949
    Abstract: The present invention relates to a class of engineered polypeptides having a binding affinity for albumin. It also relates to new methods and uses that exploit binding by these and other compounds to albumin in different contexts, some of which have significance for the treatment of disease in mammals including humans.
    Type: Grant
    Filed: November 24, 2014
    Date of Patent: November 6, 2018
    Assignee: AFFIBODY AB
    Inventors: Lars Abrahmsén, Andreas Jonsson, Jakob Dogan, Per-Åke Nygren
  • Patent number: 10118950
    Abstract: The invention relates to genomically recoded organisms, platforms for preparing sequence defined biopolymers in vitro comprising a cellular extract from a genomically recorded organism, and methods for preparing sequence defined biopolymers in vitro are described. In particular, the invention relates to genomically recoded organisms comprising a strain deficient in release factor 1 (RF-1) or a genetic homolog thereof and at least one of at least one additional genetic knock-out mutation, at least one additional upregulated gene product, or both at least one additional knock-out mutation and at least one additional upregulated gene product.
    Type: Grant
    Filed: August 31, 2015
    Date of Patent: November 6, 2018
    Assignee: NORTHWESTERN UNIVERSITY
    Inventors: Michael Christoper Jewett, Rey William Martin, Seok Hoon Hong, Yong Chan Kwon, Benjamin James Des Soye
  • Patent number: 10118951
    Abstract: The present invention relates to polymerized recombinant proteins, to recombinant nucleic acids coding for the polymerized recombinant proteins, to expression cassettes comprising the recombinant nucleic acids, to host cells transformed by the expression cassettes and to a method for multimerizing a recombinant protein. The polymerized proteins of the invention may be used in pharmaceutical or immunogenic compositions. In particular, the recombinant proteins may be antigens, antibodies or scaffolds. In particular, the polymerized recombinant protein may be an influenza haemagglutinin.
    Type: Grant
    Filed: December 18, 2015
    Date of Patent: November 6, 2018
    Assignee: Sanofi Pasteur
    Inventors: Régis Sodoyer, Isabelle Legastelois
  • Patent number: 10118952
    Abstract: The present disclosure provides hNGAL muteins that bind a pyoverdine family member or pyochelin and can be used in various application including pharmaceutical applications, for example, to inhibit or reduce growth of P. aeruginosa. The present disclosure also concerns methods of making one or more pyoverdine- or pyochelin-binding muteins described herein as well as compositions comprising one or more of such muteins. The present disclosure further relates to nucleic acid molecules encoding such muteins and to methods for generation of such muteins and nucleic acid molecules. In addition, the application discloses therapeutic and/or diagnostic uses of these muteins as well as compositions comprising one or more of such muteins.
    Type: Grant
    Filed: October 6, 2017
    Date of Patent: November 6, 2018
    Assignee: SANOFI
    Inventors: Carsten Corvey, Heike Stump, Jochen Kruip, Bernhard Calandra, Astrid Rey, Nathalie Karst, Michael Mourez, Laurent Fraisse, Christine Rothe, Andrea Allersdorfer, Alexander Wiedenmann, Marlon Hinner, Bradley Lunde, Kristian Jensen, Martin Hülsmeyer
  • Patent number: 10118953
    Abstract: The present invention refers to single-chain fusion proteins comprising three soluble TNF superfamily (TNFSF) cytokine domains and nucleic acid molecules encoding these fusion proteins. The fusion proteins are substantially non-aggregating and suitable for therapeutic, diagnostic and/or research applications.
    Type: Grant
    Filed: July 7, 2017
    Date of Patent: November 6, 2018
    Assignee: APOGENIX AG
    Inventors: Oliver Hill, Christian Gieffers, Meinolf Thiemann
  • Patent number: 10118954
    Abstract: A pharmaceutical composition with a peptide analog of apelin, and a method of treatment for various conditions are described. An exemplary embodiment is a peptide analog comprising at least residues 2-13 of SEQ ID NO: 1 and further comprising at least a substitution or modification at residue 13 of SEQ ID NO: 1. A pharmaceutical composition comprising the peptide analog of the present invention and method of treatment for diabetes, stimulating insulin release, and moderating blood glucose excursions by administering the peptide analog of the present invention to a patient in need thereof are described.
    Type: Grant
    Filed: April 29, 2015
    Date of Patent: November 6, 2018
    Assignee: Univeristy of Ulster
    Inventors: Finbarr Paul Mary O'Harte, Peter Raymond Flatt
  • Patent number: 10118955
    Abstract: C-Terminal Fragments of Glucagon-Like Peptide-1 (GLP 1), and methods of use thereof, e.g., for the treatment of obesity and obesity-related disorders, e.g., diabetes and the metabolic syndrome.
    Type: Grant
    Filed: November 12, 2014
    Date of Patent: November 6, 2018
    Assignee: The General Hospital Corporation
    Inventors: Joel F. Habener, Tatsuya Yano, Eva Tomas Falco
  • Patent number: 10118956
    Abstract: The present invention relates to the field of medicine, in particular, to the production of large amounts of a soluble recombinant polypeptide as part of a fusion protein comprising an N-terminal fusion partner linked to the polypeptide of interest.
    Type: Grant
    Filed: November 30, 2015
    Date of Patent: November 6, 2018
    Assignee: PFENEX INC.
    Inventors: Diane M. Retallack, Adam Chapman, Torben R. Bruck, Hongfan Jin
  • Patent number: 10118957
    Abstract: The invention pertains to a means for downregulating or inhibiting or mislocalizing CAR in a cardiac cell for treating/curing a patient who has suffered or is predisposed to suffering a myocardial infarction (MI) or preventing myocardial infarction or complications thereof.
    Type: Grant
    Filed: August 5, 2013
    Date of Patent: November 6, 2018
    Assignee: MAX-DELBRÜCK-CENTRUM FÜR MOLEKULARE MEDIZIN (MDC) BERLIN-BUCH
    Inventors: Michael Gotthardt, Fabian Freiberg
  • Patent number: 10118958
    Abstract: Provided herein are methods of using the antibodies that bind to RGMc to treat and diagnose iron-related disorders.
    Type: Grant
    Filed: December 13, 2012
    Date of Patent: November 6, 2018
    Assignees: ABBVIE DEUTSCHLAND GMBH & CO. KG, ABBVIE INC.
    Inventors: Bernhard Mueller, Andreas Popp, Jennifer M. Perez
  • Patent number: 10118959
    Abstract: An anti-glypican-3 antibody comprising one or more amino acid substitutions introduced in the Fc region is disclosed. Preferably, in the anti-glypican-3 antibody, one or more of the amino acid residues at the positions 239, 298, 326, 330 and 332 in the Fc region are substituted with other amino acid residues. Since the Fc-modified anti-glypican-3 antibody of the invention exhibit enhanced ADCC activity, it is useful in treating cancers, such as hepatic cancer. Also disclosed are an anticancer agent comprising the anti-glypican-3 antibody of the invention and a pharmaceutically acceptable carrier, as well as a method of treating a patient with cancer comprising administering to the patient the anticancer agent of the invention.
    Type: Grant
    Filed: October 3, 2014
    Date of Patent: November 6, 2018
    Assignees: Chugai Seiyaku Kabushiki Kaisha, Xencor, Inc.
    Inventors: Gregory Alan Lazar, Bassil I. Dahiyat, Hisafumi Okabe, Masamichi Sugimoto, Shigeyuki Iijima, Izumi Sugo
  • Patent number: 10118960
    Abstract: The present application discloses humanized 1H7 antibodies. The antibodies bind to human alpha synuclein and can be used for treatment and diagnosis of Lewy body disease.
    Type: Grant
    Filed: May 4, 2017
    Date of Patent: November 6, 2018
    Assignee: PROTHENA BIOSCIENCES LIMITED
    Inventors: Jose Saldanha, Tarlochan S. Nijjar
  • Patent number: 10118961
    Abstract: The present disclosure provides modified antibodies which contain an antibody or antibody fragment (AB) modified with a masking moiety (MM). Such modified antibodies can be further coupled to a cleavable moiety (CM), resulting in activatable antibodies (AAs), wherein the CM is capable of being cleaved, reduced, photolyzed, or otherwise modified. AAs can exhibit an activatable conformation such that the AB is more accessible to a target after, for example, removal of the MM by cleavage, reduction, or photolysis of the CM in the presence of an agent capable of cleaving, reducing, or photolyzing the CM. The disclosure further provides methods of making and using such modified antibodies and activatable antibodies.
    Type: Grant
    Filed: August 24, 2016
    Date of Patent: November 6, 2018
    Assignee: CytomX Therapeutics, Inc.
    Inventors: Nancy E. Stagliano, James William West, Kathryn Kamath, Paul Henry Bessette, Fred Gluck, Jason Gary Sagert, Patrick Daugherty
  • Patent number: 10118962
    Abstract: Processes and methods of purifying or separating Single Domain Antigen Binding (SDAB) molecules that include one or more single binding domains (e.g., one or more nanobody molecules), substantially devoid of a complementary antibody domain and an immunoglobulin constant region, using Protein A-based affinity chromatography, are disclosed.
    Type: Grant
    Filed: October 29, 2009
    Date of Patent: November 6, 2018
    Assignee: Ablynx N.V.
    Inventors: Paul R. Brown, Scott Andreas Tobler, Andrew M. Wood, Austin Wayne Boesch
  • Patent number: 10118963
    Abstract: There is disclosed anti-PD-L1 IgG class antibodies that have an improved ability to be manufactured at higher yields. More specifically, there is disclosed human antibodies that bind PD-L1, PD-L1-binding fragments that can be manufactured at higher yields.
    Type: Grant
    Filed: January 27, 2017
    Date of Patent: November 6, 2018
    Assignee: Sorrento Therapeutics, Inc.
    Inventor: Heyue Zhou
  • Patent number: 10118964
    Abstract: The present invention provides a bispecific antibody. The bispecific antibody provided by the present invention comprises a single-chain unit and a monovalent unit, wherein the single-chain unit has a specific binding capability against a surface antigen CD3 of an immune cell; the monovalent unit has a specific binding capability against a surface antigen HER2 of a tumor cell; the single-chain unit comprises a single-chain variable fragment ScFv fused with an Fc fragment; and the monovalent unit comprises a light chain and heavy chain pair. The present invention also provides a preparation method of the bispecific antibody and pharmaceutical use of these antibodies.
    Type: Grant
    Filed: March 3, 2017
    Date of Patent: November 6, 2018
    Assignee: Wuhan YZY Biopharma Co., Ltd.
    Inventors: Pengfei Zhou, Jing Zhang, Lingli Hu, Rui Wang, Xiang Zhou, Kesu Fan
  • Patent number: 10118965
    Abstract: In some aspects, the invention relates to an antibody-drug conjugate, comprising an anti-epidermal growth factor receptor (“EGFR”) antibody; a linker; and an active agent. The antibody-drug conjugate may comprise a self-immolative group. The linker may comprise an O-substituted oxime, e.g., wherein the oxygen atom of the oxime is substituted with a group that covalently links the oxime to the drug; and the carbon atom of the oxime is substituted with a group that covalently links the oxime to the antibody.
    Type: Grant
    Filed: September 26, 2016
    Date of Patent: November 6, 2018
    Assignee: LegoChem Biosciences, Inc.
    Inventors: Yong Zu Kim, Yun Hee Park, Hyo Jung Choi, Ji Eun Jung, Jeong Hee Ryu, Ho Young Song, Jeiwook Chae, Chul-Woong Chung
  • Patent number: 10118966
    Abstract: The present invention provides a method for producing an anti-EGFR monoclonal antibody and the applications thereof. The method comprises the steps of: designing and synthesizing the light chain and heavy chain according to the codons preferred by Chinese hamster, transfecting GS knockout host cells CHO-CR-GS?/?, culturing cells using serum-free technology, isolating and purifying the antibody, and obtaining the low immunogenicity CMAB009 antibody.
    Type: Grant
    Filed: January 4, 2016
    Date of Patent: November 6, 2018
    Assignee: Shanghai Biomabs Pharmaceuticals Co., Ltd.
    Inventor: Weizhu Qian
  • Patent number: 10118967
    Abstract: Methods are provided for the treatment of IL-6R related diseases. More specifically, specific dose regimens and pre-filled syringes are provided for subcutaneous administration, to subjects suffering an IL-6R related disease, of immunoglobulin single variable domains that bind IL-6R.
    Type: Grant
    Filed: October 21, 2015
    Date of Patent: November 6, 2018
    Assignee: Ablynx N.V.
    Inventors: Sven Hoefman, Maria Laura Sargentini-Maier, Katrien Van Beneden
  • Patent number: 10118968
    Abstract: The present invention relates to novel antibodies, particularly antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to the type III deletion mutant, EGFRvIII. The invention also relates to human monoclonal antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to EGFRvIII. Diagnostic and therapeutic formulations of such antibodies, and immunoconjugates thereof, are also provided.
    Type: Grant
    Filed: December 29, 2009
    Date of Patent: November 6, 2018
    Assignee: Amgen Fremont Inc.
    Inventors: Richard Weber, Xiao Feng, Orit Foord, Larry Green, Jean M. Gudas, Bruce Keyt, Ying Liu, Palaniswami Rathanaswami, Robert Raya, Xiao Dong Yang, Jose Corvalan, Ian Foltz, Xiao-Chi Jia, Jaspal S. Kang, Chadwick T. King, Scott L. Klakamp, Qiaojuan Jane Su
  • Patent number: 10118969
    Abstract: The present disclosure relates to compositions and methods of use comprising antibodies or binding fragments thereof further comprising universal Fc glycoforms.
    Type: Grant
    Filed: January 30, 2016
    Date of Patent: November 6, 2018
    Assignee: ACADEMIA SINICA
    Inventors: Chi-Huey Wong, Chung-Yi Wu, Che Ma, Han-Chung Wu
  • Patent number: 10118970
    Abstract: The invention provides multispecific antibodies and methods of making and using such antibodies. In general, the multispecific antibodies are made by methods involving the steps of altering the nucleic acid sequence encoding the light chain variable domain (VL) of an antibody that binds a first epitope, and selecting a multispecific antibody capable of binding the first and a second epitope.
    Type: Grant
    Filed: August 17, 2007
    Date of Patent: November 6, 2018
    Assignee: Genentech, Inc.
    Inventors: Germaine Fuh, Jenny M. Bostrom
  • Patent number: 10118971
    Abstract: The present invention provides a protein or antibody in which, of a pair of hydrophobic amino acids selected from within a hydrophobic interaction site of the protein, one hydrophobic amino acid is transformed into a substance having a positive electrical charge and the other hydrophobic amino acid is transformed into a substance having a negative electrical charge, and electrostatic interaction is introduced within the hydrophobic interaction site of the protein by means of the positive charge and the negative charge. The present invention also provides a method for preparing the protein or antibody, and a method for measuring the degree of coupling between a heavy chain and a light chain, using the antibody. The protein or antibody in accordance with to the present invention has a low contamination by a homodimer or a monomer, and thus a heterodimer can be obtained in high purity.
    Type: Grant
    Filed: March 13, 2014
    Date of Patent: November 6, 2018
    Assignee: IBENTRUS, INC.
    Inventor: Hoeon Kim
  • Patent number: 10118972
    Abstract: As an antitumor drug which is excellent in terms of antitumor effect and safety and has an excellent therapeutic effect, there is provided an antibody-drug conjugate in which an antitumor compound represented by the following formula is conjugated to an anti-HER2 antibody via a linker having a structure represented by the following formula: -L1-L2-LP-NH—(CH2)n1-La-(CH2)n2-C(?O)— wherein the anti-HER2 antibody is connected to the terminal L1, and the antitumor compound is connected to the carbonyl group of the —(CH2)n2-C(?O)— moiety with the nitrogen atom of the amino group at position 1 as the connecting position.
    Type: Grant
    Filed: July 28, 2016
    Date of Patent: November 6, 2018
    Assignee: DAIICHI SANKYO COMPANY, LIMITED
    Inventors: Hiroyuki Naito, Yusuke Ogitani, Takeshi Masuda, Takashi Nakada, Masao Yoshida, Shinji Ashida, Koji Morita, Hideki Miyazaki, Yuji Kasuya, Ichiro Hayakawa, Yuki Abe
  • Patent number: 10118973
    Abstract: There is disclosed a modified conjugated diene polymer including a structural unit derived from a compound represented by formula (1), and a structural unit derived from a conjugated diene. When n is 0, at least two of R11, R12, R13, R16, R17 and R18 are substituted amino groups, and at least one is a hydroxy group or hydrocarbyloxy group.
    Type: Grant
    Filed: December 24, 2015
    Date of Patent: November 6, 2018
    Assignee: SUMITOMO CHEMICAL COMPANY, LIMITED
    Inventor: Koichiro Tajima
  • Patent number: 10118974
    Abstract: Disclosed are a modified conjugated diene-based polymer represented by a specific Chemical Formula and a method of preparing the same.
    Type: Grant
    Filed: November 3, 2015
    Date of Patent: November 6, 2018
    Assignee: LG Chem, Ltd.
    Inventors: Hae-Sung Sohn, No-Ma Kim, He-Seung Lee
  • Patent number: 10118975
    Abstract: Disclosed herein are catalyst compositions containing bicyclic bridged metallocene compounds. These catalyst compositions can be used for the polymerization of olefins. For example, ethylene polymers produced using these catalyst compositions can be characterized by low molecular weights and high melt flow rates, and can be produced without the addition of hydrogen.
    Type: Grant
    Filed: August 10, 2017
    Date of Patent: November 6, 2018
    Assignee: Chevron Phillips Chemical Company LP
    Inventors: Jeremy M. Praetorius, Qing Yang, Connor D. Boxell, Tony R. Crain
  • Patent number: 10118976
    Abstract: Anion-coordinating polymers comprising one or more anion-coordinating unit of Formula (I), optionally in combination with one or more cation-coordinating unit of Formula (II) and/or a linking unit of Formula (III) and related electrolytes, batteries, methods and system.
    Type: Grant
    Filed: January 4, 2017
    Date of Patent: November 6, 2018
    Assignees: CALIFORNIA INSTITUTE OF TECHNOLOGY, CORNELL UNIVERSITY
    Inventors: Brett M. Savoie, Michael A. Webb, Robert H. Grubbs, Thomas F. Miller, III, Geoffrey W. Coates, Qi Zheng
  • Patent number: 10118977
    Abstract: This invention relates to a solid MgCl2 based Natta catalyst component for producing olefin polymers and preparation of said catalyst component. Further the invention relates to a Ziegler Natta catalyst comprising said solid catalyst component, Group 13 metal compound as cocatalyst and optionally external additives. The invention further relates to the use of said catalyst component in producing olefin polymers, especially ethylene polymers with desired properties.
    Type: Grant
    Filed: December 17, 2015
    Date of Patent: November 6, 2018
    Assignee: Borealis AG
    Inventors: Victor Sumerin, Joseph Thorman
  • Patent number: 10118978
    Abstract: Provided by the present invention is a vinyl alcohol polymer crosslinked by a structure represented by the following formula (1) and/or a disulfide structure, in which the vinyl alcohol polymer is not completely dissolved in a mixture prepared by: adding the vinyl alcohol polymer to water so as to give a concentration of 4% by mass; and stirring at 95° C. for 3 hrs. in the formula (1), R1, R2 and R3 each independently represent a hydrogen atom or a substituted or unsubstituted hydrocarbon group having 8 or less carbon atoms. Also provided include an additive for a drilling mud containing the vinyl alcohol polymer, a drilling mud containing the vinyl alcohol polymer as an additive, an additive for a drilling cement slurry containing the vinyl alcohol polymer, and a drilling cement slurry containing the vinyl alcohol polymer as an additive.
    Type: Grant
    Filed: September 11, 2014
    Date of Patent: November 6, 2018
    Assignee: KURARAY CO., LTD.
    Inventors: Yosuke Kumaki, Yasutomo Saito
  • Patent number: 10118979
    Abstract: Provided is a binder that has satisfactory storage stability and can express an excellent bonding strength for a glass fiber or powdered glass (impart a satisfactory strength to a bonded body with the glass fiber or the powdered glass).
    Type: Grant
    Filed: September 17, 2015
    Date of Patent: November 6, 2018
    Assignee: NIPPON SHOKUBAI CO., LTD.
    Inventors: Ikuo Shimizu, Takashi Yamamoto
  • Patent number: 10118980
    Abstract: Polymer particle embolics and methods of making same are described. The particle embolics can be used as embolization agents.
    Type: Grant
    Filed: May 24, 2017
    Date of Patent: November 6, 2018
    Assignee: Terumo Corporation
    Inventors: Steve Plotkin, Gregory M. Cruise, Edward Michael Keeley, Renee Yu, Clayton Harris
  • Patent number: 10118981
    Abstract: The invention provides lactamic polymers comprising an acetoacetate moiety. The lactamic polymers may be readily functionalized and the functionalized lactamic polymers may be further derivatized to provide a wide variety of useful polymers having desirable chemical and physical properties. The lactamic polymers of the invention may be employed in a wide variety of compositions. (A); (B) wherein R1-R6, w, x, y, z, and n are described herein.
    Type: Grant
    Filed: October 7, 2016
    Date of Patent: November 6, 2018
    Assignee: ISP Investments LLC
    Inventors: David K. Hood, Karyn B. Visscher, Surya Kamin, Sounak Sarkar
  • Patent number: 10118982
    Abstract: Provided is a graft copolymer (A) obtainable by graft-polymerizing, in the presence of 30 to 80 parts by mass of an ethylene-based polymer (a), an aromatic vinyl-based monomer (b) and, if necessary, another vinyl-based monomer (c) copolymerizable with the aromatic vinyl-based monomer (b) in a total amount of 20 to 70 parts by mass (provided that the sum of the components (a), (b) and (c) is 100 parts by mass), in which the ethylene-based polymer (a) has a density of 0.900 g/cm3 or more and less than 0.966 g/cm3, a number average molecular weight of 10,000 to 50,000, and a molecular weight distribution of 5 to 15, and the proportion of the ethylene-based polymer (a) molecules having a molecular weight of 10,000 or less is 5.5% or more.
    Type: Grant
    Filed: April 17, 2015
    Date of Patent: November 6, 2018
    Assignee: NIPPON A&L INC.
    Inventors: Kazuhiro Ishigaki, Kiyoshi Ikawa, Taisuke Yukawa
  • Patent number: 10118983
    Abstract: Treated aldehyde-based resins containing one or more polyamines and methods for making and same. The treated aldehyde-based resin can be or include an aldehyde-based resin and a polyamine. The polyamine can be or include one or more aromatic polyamines, one or more poly(C2-C5 alkylene) polyamines, or a mixture thereof. The treated aldehyde-based resin can include about 0.05 wt % to about 10 wt % of the polyamine, based on a solids weight of the aldehyde-based resin.
    Type: Grant
    Filed: April 8, 2016
    Date of Patent: November 6, 2018
    Assignee: Georgia-Pacific Chemicals LLC
    Inventor: Richard A. Rediger
  • Patent number: 10118984
    Abstract: A silylated polyurethane obtainable by a process comprising the following steps: (a) reacting at least one polyol with at least one triisocyanate to form a hydroxyl-terminated polyurethane prepolymer, and (b) reacting said polyurethane prepolymer with at least one isocyanatosilane of the formula (1): OCN—R—Si—(X)m(R1)3?m, wherein m is 0, 1 or 2, each R1 is independently from each other a hydroxyl group, an alkoxy group having 1 to 10 carbon atoms, an acyloxy group having 1 to 10 carbon atoms, or —OCH(R2)COOR3, wherein R2 is hydrogen or an alkyl group having 1 to 4 carbon atoms and R3 is a straight-chain or branched alkyl group having 1 to 8 carbon atoms, each X is independently from each other and optionally substituted hydrocarbon group having 1 to 10 carbon atoms, which can be interrupted by at least one heteroatom, and R is a difunctional organic group, to endcap the hydroxyl groups on said prepolymer with said isocyanatosilane.
    Type: Grant
    Filed: September 7, 2017
    Date of Patent: November 6, 2018
    Assignee: Henkel AG & Co. KGaA
    Inventors: Ralf Bätzgen, Jan-Erik Damke, David Briers, Johann Klein